DK1305334T3 - Urocortinproteiner og anvendelser deraf - Google Patents
Urocortinproteiner og anvendelser derafInfo
- Publication number
- DK1305334T3 DK1305334T3 DK01963759T DK01963759T DK1305334T3 DK 1305334 T3 DK1305334 T3 DK 1305334T3 DK 01963759 T DK01963759 T DK 01963759T DK 01963759 T DK01963759 T DK 01963759T DK 1305334 T3 DK1305334 T3 DK 1305334T3
- Authority
- DK
- Denmark
- Prior art keywords
- ucn
- crf
- urp
- urocortin
- human
- Prior art date
Links
- 108010059705 Urocortins Proteins 0.000 title abstract 6
- 102000005630 Urocortins Human genes 0.000 title abstract 6
- 239000000777 urocortin Substances 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 101000658084 Homo sapiens U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 abstract 3
- 101000841331 Homo sapiens Urotensin-2B Proteins 0.000 abstract 3
- 102000057476 human UTS2B Human genes 0.000 abstract 3
- 108091005470 CRHR2 Proteins 0.000 abstract 2
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 abstract 2
- 108090000189 Neuropeptides Proteins 0.000 abstract 2
- 101710166315 U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 abstract 2
- 102100029789 Urocortin-2 Human genes 0.000 abstract 2
- 230000033228 biological regulation Effects 0.000 abstract 2
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 abstract 1
- 101710198652 Corticotropin-releasing factor receptor 1 Proteins 0.000 abstract 1
- 101000939391 Homo sapiens Urocortin Proteins 0.000 abstract 1
- 101000939386 Mus musculus Urocortin-2 Proteins 0.000 abstract 1
- 102000003797 Neuropeptides Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 102000053170 human UCN Human genes 0.000 abstract 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- ZEBBPGHOLWPSGI-KPLDDXDLSA-N urocortin ii Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CS)C(N)=O)CC1=CN=CN1 ZEBBPGHOLWPSGI-KPLDDXDLSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22325500P | 2000-08-04 | 2000-08-04 | |
| US27396901P | 2001-03-07 | 2001-03-07 | |
| PCT/US2001/023976 WO2002012307A1 (en) | 2000-08-04 | 2001-07-31 | Urocortin proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1305334T3 true DK1305334T3 (da) | 2009-02-02 |
Family
ID=26917597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01963759T DK1305334T3 (da) | 2000-08-04 | 2001-07-31 | Urocortinproteiner og anvendelser deraf |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US6838274B2 (enExample) |
| EP (1) | EP1305334B1 (enExample) |
| JP (1) | JP4873825B2 (enExample) |
| KR (1) | KR100879232B1 (enExample) |
| CN (1) | CN1484650B (enExample) |
| AT (1) | ATE408622T1 (enExample) |
| AU (2) | AU8468301A (enExample) |
| CA (1) | CA2418144C (enExample) |
| CY (1) | CY1110424T1 (enExample) |
| DE (1) | DE60135850D1 (enExample) |
| DK (1) | DK1305334T3 (enExample) |
| ES (1) | ES2313978T3 (enExample) |
| IL (2) | IL154102A0 (enExample) |
| PT (1) | PT1305334E (enExample) |
| RU (1) | RU2278871C2 (enExample) |
| WO (1) | WO2002012307A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60135850D1 (de) * | 2000-08-04 | 2008-10-30 | Res Dev Foundation | Urocortinproteine und deren verwendungen |
| US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| CA2425902C (en) * | 2001-03-15 | 2017-01-03 | Research Development Foundation | Urocortin-iii and uses thereof |
| US6936585B2 (en) | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| US7982018B2 (en) * | 2006-10-16 | 2011-07-19 | Conjuchem, Llc | Modified corticotropin releasing factor peptides and uses thereof |
| CA2692039C (en) | 2007-06-13 | 2019-07-02 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
| RU2010113986A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение пептида в качестве терапевтического средства |
| KR20100057063A (ko) * | 2007-09-11 | 2010-05-28 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드의 용도 |
| US20120238509A1 (en) * | 2009-08-28 | 2012-09-20 | Research Development Foundation | Urocortin 2 analogs and uses thereof |
| WO2013063046A1 (en) | 2011-10-24 | 2013-05-02 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
| KR102107482B1 (ko) | 2012-02-14 | 2020-05-08 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현 |
| JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| US12472158B2 (en) | 2019-02-27 | 2025-11-18 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| CN110826145B (zh) * | 2019-09-09 | 2020-08-28 | 西安工业大学 | 基于超启发式马氏链进化的汽车多参数运行工况设计方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6277796A (en) | 1995-06-13 | 1997-01-15 | Salk Institute For Biological Studies, The | Urocortin peptides |
| DE60135850D1 (de) | 2000-08-04 | 2008-10-30 | Res Dev Foundation | Urocortinproteine und deren verwendungen |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
-
2001
- 2001-07-31 DE DE60135850T patent/DE60135850D1/de not_active Expired - Lifetime
- 2001-07-31 DK DK01963759T patent/DK1305334T3/da active
- 2001-07-31 RU RU2003105897/13A patent/RU2278871C2/ru not_active IP Right Cessation
- 2001-07-31 KR KR1020037001559A patent/KR100879232B1/ko not_active Expired - Fee Related
- 2001-07-31 CN CN018157831A patent/CN1484650B/zh not_active Expired - Fee Related
- 2001-07-31 AT AT01963759T patent/ATE408622T1/de active
- 2001-07-31 AU AU8468301A patent/AU8468301A/xx active Pending
- 2001-07-31 WO PCT/US2001/023976 patent/WO2002012307A1/en not_active Ceased
- 2001-07-31 JP JP2002518278A patent/JP4873825B2/ja not_active Expired - Fee Related
- 2001-07-31 ES ES01963759T patent/ES2313978T3/es not_active Expired - Lifetime
- 2001-07-31 EP EP01963759A patent/EP1305334B1/en not_active Expired - Lifetime
- 2001-07-31 PT PT01963759T patent/PT1305334E/pt unknown
- 2001-07-31 AU AU2001284683A patent/AU2001284683B2/en not_active Ceased
- 2001-07-31 CA CA2418144A patent/CA2418144C/en not_active Expired - Fee Related
- 2001-07-31 IL IL15410201A patent/IL154102A0/xx unknown
- 2001-07-31 US US09/919,473 patent/US6838274B2/en not_active Expired - Lifetime
-
2003
- 2003-01-23 IL IL154102A patent/IL154102A/en not_active IP Right Cessation
-
2004
- 2004-10-25 US US10/973,092 patent/US7223846B2/en not_active Expired - Lifetime
-
2007
- 2007-04-05 US US11/784,317 patent/US7638607B2/en not_active Expired - Fee Related
-
2008
- 2008-12-17 CY CY20081101461T patent/CY1110424T1/el unknown
-
2009
- 2009-12-07 US US12/632,715 patent/US8044025B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2003105897A (ru) | 2005-01-20 |
| AU2001284683B2 (en) | 2006-04-27 |
| EP1305334B1 (en) | 2008-09-17 |
| CA2418144A1 (en) | 2002-02-14 |
| US7638607B2 (en) | 2009-12-29 |
| EP1305334A4 (en) | 2005-03-23 |
| US6838274B2 (en) | 2005-01-04 |
| RU2278871C2 (ru) | 2006-06-27 |
| PT1305334E (pt) | 2008-12-30 |
| CA2418144C (en) | 2013-06-18 |
| US20070191592A1 (en) | 2007-08-16 |
| ATE408622T1 (de) | 2008-10-15 |
| JP2004505640A (ja) | 2004-02-26 |
| US20020127221A1 (en) | 2002-09-12 |
| IL154102A (en) | 2010-12-30 |
| ES2313978T3 (es) | 2009-03-16 |
| IL154102A0 (en) | 2003-07-31 |
| JP4873825B2 (ja) | 2012-02-08 |
| EP1305334A1 (en) | 2003-05-02 |
| CY1110424T1 (el) | 2015-04-29 |
| US20100168021A1 (en) | 2010-07-01 |
| CN1484650A (zh) | 2004-03-24 |
| AU8468301A (en) | 2002-02-18 |
| US7223846B2 (en) | 2007-05-29 |
| US20050191650A1 (en) | 2005-09-01 |
| DE60135850D1 (de) | 2008-10-30 |
| KR20030074589A (ko) | 2003-09-19 |
| US8044025B2 (en) | 2011-10-25 |
| CN1484650B (zh) | 2012-12-12 |
| KR100879232B1 (ko) | 2009-01-20 |
| WO2002012307A1 (en) | 2002-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110424T1 (el) | Πρωτεϊνες ουροκορτινης και χρησεις αυτων | |
| Zhao et al. | The purification and partial amino acid sequence of a polypeptide from the glutelin fraction of rice grains; homology to pea legumin | |
| Graham et al. | Complete amino acid sequence of soybean leaf P21: similarity to the thaumatin-like polypeptides | |
| Crabb et al. | Characterization of multiple forms of prostatropin (prostate epithelial cell growth factor) from bovine brain | |
| Schmelzer et al. | Biochemical characterization of recombinant human nerve growth factor | |
| Browning et al. | Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers | |
| ATE455792T1 (de) | Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon | |
| Lund et al. | The human chromosomal protein HMG I contains two identical palindrome amino acid sequences | |
| Higuchi et al. | The single proline‐glutamine substitution at position 5 enhances the potency of amyloid fibril formation of murine apo A‐II | |
| Minchiotti et al. | Two alloalbumins with identical electrophoretic mobility are produced by differently charged amino acid substitutions | |
| Araki et al. | The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure | |
| Leszyk et al. | Amino acid sequence of a 15 kilodalton actin-binding fragment of turkey gizzard caldesmon: Similarity with dystrophin, tropomysin and the tropomyosin-binding region of troponin T | |
| Shamoo et al. | Cloning of T4 gene 32 and expression of the wild-type protein under lambda promoter PL regulation in Escherichia coli. | |
| ATE287952T1 (de) | Humanes thymosin beta 15 gen,protein und dessen verwendungen | |
| Harper et al. | Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor | |
| Reid | Amino acid sequence of the N-terminal forty-two amino acid residues of the C chain of subcomponent C1q of the first component of human complement | |
| Lundwall et al. | Chemical characterization of cyanogen bromide fragments from the β‐chain of human complement factor C3 | |
| Zhang et al. | Oxidative folding of hepcidin at acidic pH | |
| Yoo et al. | Identification of the secretory vesicle membrane binding region of chromogranin B | |
| Boumaiza et al. | Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1 | |
| Liu et al. | Identification of a novel S-superfamily conotoxin from vermivorous Conus caracteristicus | |
| Brandt et al. | The amino acid sequence of wheat histone H2B (2) A core histone with a novel repetitive N‐terminal extension | |
| Wang et al. | Purification of heparin‐binding protein HBp17 and identification of HBp17 heparin binding site | |
| Karlson et al. | The amino acid sequence of the chromosomal protein HMG-Y, its relation to HMG-I and possible domains for the preferential binding of the proteins to stretches of AT base pairs | |
| Strasser et al. | Variable and constant regions in the C‐terminus of vinculin and metavinculin: Cloning and expression of fragments in E. coli |